Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Opus Genetics, Inc.NASDAQ: IRD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $65.54M (cash outflow) rose 699.8% year over year, ahead of the +82.4% change in trailing-twelve-month net income. Sequentially, it rose 296.6% from the prior quarter.
Context
- Net income amounted to 349.3% of revenue in FY2025, down 174.1 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 13 analysts of -$73.4M (+48.0%) for the fiscal year ending Dec 2026, a step up from the -13.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$65.54M+296.6% QoQ
- Last fiscal yearDec 2025
- -$49.59M-13.8% YoY
- LTMMar 2026
- -$106.93M+82.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +699.8% | +115.0% | -584.8 pp |
| 1 year | -13.8% | +48.0% | +61.8 pp |
| 3-year CAGR | — | -12.5% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (49.59M) USD
- Year-over-year change
- +13.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.59M) | +13.8% |
| FY2024 | 2024-12-31 | (57.53M) | -476.1% |
| FY2023 | 2023-12-31 | (9.99M) | -155.8% |
| FY2022 | 2022-12-31 | 17.89M | +131.6% |
| FY2021 | 2021-12-31 | (56.69M) | — |
Net Income vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 net income of $106.93M is the 3rd largest of the 10 companies compared; the peer median is $47.38M.
- Its year-over-year change of +82.4% is the 2nd highest of 9, against a peer median of -14.9%.
- Net income amounts to 892.4% of revenue for IRD, versus a peer median of 574.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.39M | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $47.38M | -39.3% | -31.6% | — | |
| LTM Mar 2026 | $46.9M | -164.3% | — | 4088.8% | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| Peer median (excluding IRD) | $47.38M | -14.9% | +1.3% | 574.8% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.91M | 1.81M | 3.51M | 3.36M | 3.4M |
| Change in Working Capital | 181K | (5.56M) | 4.08M | 3.09M | (2.15M) |
| Accounts Receivables | 0 | (4.85M) | 2.52M | (3.44M) | 2.61M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 381K | (515K) | 1.08M | 220K | 7K |
| Other Working Capital | (200K) | (190K) | 477K | 6.31M | (4.77M) |
| Other Non-Cash Items | 35.22M | 170K | 1.28M | 25.49M | 13.04M |
| Operating Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (100K) | 0 | 0 | 1.21M | 0 |
| Investing Cash Flow | (100K) | 0 | 0 | 1.21M | 0 |
| Debt Repayment | 538K | (538K) | 0 | 0 | 1M |
| Common Stock Issued | 28.49M | 4.43M | 9.23M | 4.5M | 49.18M |
| Common Stock Repurchased | 0 | 0 | 0 | (79K) | (152K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.42M) | (104K) | (248K) | (232K) | 0 |
| Financing Cash Flow | 27.61M | 3.79M | 8.98M | 4.19M | 50.02M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.14M | 18.1M | 7.87M | (20.18M) | 14.77M |
| Free Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.